annb0t
Top 20
Summary of Study Outcomes
ZIRCON Phase III study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) has met all of its primary and secondary endpoints The study delivered co-primary endpoints of 86% sensitivity and 87% specificity and 93% positive predictive value (secondary endpoint) considerably exceeding sensitivity and specificity targets These ground-breaking results indicate that TLX250-CDx has the potential to become a new clinical standard in ...
>>> Read more: Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study
ZIRCON Phase III study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) has met all of its primary and secondary endpoints The study delivered co-primary endpoints of 86% sensitivity and 87% specificity and 93% positive predictive value (secondary endpoint) considerably exceeding sensitivity and specificity targets These ground-breaking results indicate that TLX250-CDx has the potential to become a new clinical standard in ...
>>> Read more: Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study
